Evidence-Based Review of Therapies in Multiple Myeloma

Michael Sebag, Alexander Keith Stewart, Ralph M. Meyer

Research output: Chapter in Book/Report/Conference proceedingChapter

Original languageEnglish (US)
Title of host publicationEvidence-Based Hematology
PublisherJohn Wiley and Sons
Pages390-395
Number of pages6
ISBN (Print)9781405157476
DOIs
StatePublished - Feb 4 2009

Fingerprint

Multiple Myeloma
L-Lactate Dehydrogenase
Therapeutics

Keywords

  • Bortezomib superior to dexamethasone in relapsed/refractory myeloma
  • High dose therapy followed by stem cell transplant and improved outcomes
  • Lactate dehydrogenase (LDH)
  • Lenalidomide role in patients with relapsed or refractory myeloma
  • Literature-search strategy and inclusions
  • Multiplemyeloma (MM) - second most common hematological malignancy in adults
  • Phase III Trials comparing stem cell transplantation with conventional chemotherapy
  • Therapies in multiple myeloma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sebag, M., Stewart, A. K., & Meyer, R. M. (2009). Evidence-Based Review of Therapies in Multiple Myeloma. In Evidence-Based Hematology (pp. 390-395). John Wiley and Sons. https://doi.org/10.1002/9781444300857.ch50

Evidence-Based Review of Therapies in Multiple Myeloma. / Sebag, Michael; Stewart, Alexander Keith; Meyer, Ralph M.

Evidence-Based Hematology. John Wiley and Sons, 2009. p. 390-395.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sebag, M, Stewart, AK & Meyer, RM 2009, Evidence-Based Review of Therapies in Multiple Myeloma. in Evidence-Based Hematology. John Wiley and Sons, pp. 390-395. https://doi.org/10.1002/9781444300857.ch50
Sebag M, Stewart AK, Meyer RM. Evidence-Based Review of Therapies in Multiple Myeloma. In Evidence-Based Hematology. John Wiley and Sons. 2009. p. 390-395 https://doi.org/10.1002/9781444300857.ch50
Sebag, Michael ; Stewart, Alexander Keith ; Meyer, Ralph M. / Evidence-Based Review of Therapies in Multiple Myeloma. Evidence-Based Hematology. John Wiley and Sons, 2009. pp. 390-395
@inbook{0c2729f7b1a94721820bc114d9d0f58a,
title = "Evidence-Based Review of Therapies in Multiple Myeloma",
keywords = "Bortezomib superior to dexamethasone in relapsed/refractory myeloma, High dose therapy followed by stem cell transplant and improved outcomes, Lactate dehydrogenase (LDH), Lenalidomide role in patients with relapsed or refractory myeloma, Literature-search strategy and inclusions, Multiplemyeloma (MM) - second most common hematological malignancy in adults, Phase III Trials comparing stem cell transplantation with conventional chemotherapy, Therapies in multiple myeloma",
author = "Michael Sebag and Stewart, {Alexander Keith} and Meyer, {Ralph M.}",
year = "2009",
month = "2",
day = "4",
doi = "10.1002/9781444300857.ch50",
language = "English (US)",
isbn = "9781405157476",
pages = "390--395",
booktitle = "Evidence-Based Hematology",
publisher = "John Wiley and Sons",

}

TY - CHAP

T1 - Evidence-Based Review of Therapies in Multiple Myeloma

AU - Sebag, Michael

AU - Stewart, Alexander Keith

AU - Meyer, Ralph M.

PY - 2009/2/4

Y1 - 2009/2/4

KW - Bortezomib superior to dexamethasone in relapsed/refractory myeloma

KW - High dose therapy followed by stem cell transplant and improved outcomes

KW - Lactate dehydrogenase (LDH)

KW - Lenalidomide role in patients with relapsed or refractory myeloma

KW - Literature-search strategy and inclusions

KW - Multiplemyeloma (MM) - second most common hematological malignancy in adults

KW - Phase III Trials comparing stem cell transplantation with conventional chemotherapy

KW - Therapies in multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=84891019275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891019275&partnerID=8YFLogxK

U2 - 10.1002/9781444300857.ch50

DO - 10.1002/9781444300857.ch50

M3 - Chapter

SN - 9781405157476

SP - 390

EP - 395

BT - Evidence-Based Hematology

PB - John Wiley and Sons

ER -